FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to haematology, cardiology and endocrinology, and concerns normalising endotheliocytemia in arterial hypertension with impaired glucose tolerance. It is ensured by complex therapy that involves graduated physical activities, as well as introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during 1.5 months.
EFFECT: invention provides effective correction of endotheliocytemia owing to potentiation of therapeutic effect of certain components of the complex therapy; than in turn allows reducing risk of thrombotic complications in the given group of patients.
1 ex
